BRCA1/2突变携带者乳腺癌筛查成像方式成本效益分析系统综述数据集

数据集获取（Figshare）

• 源站标题：DataSheet_2_Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.doc
• DOI：10.3389/fonc.2021.763161.s002
• 发布日期：2022-01-10
• 文件数：1 个
• 文件总体积：954.88 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_2_Cost-Effectiveness_Analysis_of_Imaging_Modalities_for_Breast_Cancer_Surveillance_Among_BRCA1_2_Mutation_Carriers_A_Systematic_Review_doc/18104432

命令行下载

curl -L -o "DataSheet_2_Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.doc" "https://ndownloader.figshare.com/files/32845814"

文件清单

• DataSheet_2_Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.doc（954.88 KB）

文件总体积 954.88 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundBRCA1/2 mutation carriers are suggested with regular breast cancer surveillance screening strategies using mammography with supplementary MRI as an adjunct tool in Western countries. From a cost-effectiveness perspective, however, the benefits of screening modalities remain controversial among different mutated genes and screening schedules.
MethodsWe searched the MEDLINE/PubMed, Embase, Cochrane Library, Scopus, and Web of Science databases to collect and compare the results of different cost-effectiveness analyses. A simulated model was used to predict the impact of screening strategies in the target group on cost, life-year gained, quality-adjusted life years, and incremental cost-effectiveness ratio (ICER).
ResultsNine cost-effectiveness studies were included. Combined mammography and MRI strategy is cost-effective in BRCA1 mutation carriers for the middle-aged group (age 35 to 54). BRCA2 mutation carriers are less likely to benefit from adjunct MRI screening, which implies that mammography alone would be sufficient from a cost-effectiveness perspective, regardless of dense breast cancer.
ConclusionsPrecision screening strategies among BRCA1/2 mutation carriers should be conducted according to the acceptable ICER, i.e., a combination of mammography and MRI for BRCA1 mutation carriers and mammography alone for BRCA2 mutation carriers.
Systematic Review RegistrationPROSPERO, identifier CRD42020205471.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2021.763161.s002（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_2_Cost-Effectiveness_Analysis_of_Imaging_Modalities_for_Breast_Cancer_Surveillance_Among_BRCA1_2_Mutation_Carriers_A_Systematic_Review_doc/18104432）。